Novel substituted 5-methyl-4-acylaminoisoxazoles as antimitotic agents: Evaluation of selectivity to LNCaP cancer cells.
Sadovnikov KS, Vasilenko DA, Gracheva YA, Zefirov NA, Radchenko EV, Palyulin VA, Grishin YK, Vasilichin VA, Shtil AA, Shevtsov PN, Shevtsova EF, Kuznetsova TS, Kuznetsov SA, Bunev AS, Zefirova ON, Milaeva ER, Averina EB.
Sadovnikov KS, et al. Among authors: bunev as.
Arch Pharm (Weinheim). 2022 May;355(5):e2100425. doi: 10.1002/ardp.202100425. Epub 2022 Feb 1.
Arch Pharm (Weinheim). 2022.
PMID: 35103336